Table 3.
Relation of the SII Level and Primary Endpoint in Patients with Different Glycemic Metabolism Status
| Variables | Events/Subjects | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI)* | P value | ||
| Whole cohort | |||||
| SII-L | 301/5475 | Reference | NA | Reference | NA |
| SII-H | 221/3127 | 1.30 (1.09–1.55) | 0.003 | 1.21 (1.01–1.46) | 0.037 |
| Ln SII (per 1-unit) | 1.23 (1.05–1.45) | 0.013 | 1.12 (0.94–1.33) | 0.201 | |
| T2DM cohort | |||||
| SII-L | 166/2516 | Reference | NA | Reference | NA |
| SII-H | 129/1440 | 1.39 (1.10–1.74) | 0.005 | 1.31 (1.03–1.67) | 0.028 |
| Ln SII (per 1-unit) | 1.36 (1.11–1.66) | 0.003 | 1.29 (1.03–1.61) | 0.024 | |
| Non-T2DM cohort | |||||
| SII-L | 135/2959 | Reference | NA | Reference | NA |
| SII-H | 92/1687 | 1.20 (0.92–1.57) | 0.174 | 1.11 (0.84–1.46) | 0.476 |
| Ln SII (per 1-unit) | 1.03 (0.80–1.34) | 0.800 | 0.93 (0.70–1.22) | 0.585 | |
Notes: *Model adjusted for age, male, hypertension, dyslipidemia, prior MI, prior PCI/CABG, hsCRP, creatinine, LM/three-vessel disease, CTO, number of stents, SYNTAX score, total length of stents and average diameter of stents.
Abbreviations: HR, hazard ratio; CI, confidence interval; NA, not applicable; SII, systematic immune-inflammation index; T2DM, type 2 diabetes mellitus; SYNTAX, synergy between PCI with taxus and cardiac surgery.